192 related articles for article (PubMed ID: 32920198)
21. Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; Chen H; Wu Z; Yang J; White SW; Miller DD; Li W
J Med Chem; 2018 Sep; 61(17):7877-7891. PubMed ID: 30122035
[TBL] [Abstract][Full Text] [Related]
22. [Effect of trichostatin A and paclitaxel on the growth and apoptosis of lung adenocarcinoma cell lines].
Zhang S; Wang XA; Zhang QC; Jiang SJ
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):492-6. PubMed ID: 22967465
[TBL] [Abstract][Full Text] [Related]
23. VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway.
Kashyap VK; Dan N; Chauhan N; Wang Q; Setua S; Nagesh PKB; Malik S; Batra V; Yallapu MM; Miller DD; Li W; Hafeez BB; Jaggi M; Chauhan SC
Cancer Lett; 2020 Feb; 470():64-74. PubMed ID: 31809801
[TBL] [Abstract][Full Text] [Related]
24. Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.
Deng S; Krutilina RI; Hartman KL; Chen H; Parke DN; Wang R; Mahmud F; Ma D; Lukka PB; Meibohm B; Seagroves TN; Miller DD; Li W
Mol Cancer Ther; 2022 Jul; 21(7):1103-1114. PubMed ID: 35499388
[TBL] [Abstract][Full Text] [Related]
25. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
26. Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
Hernández-Prat A; Rodriguez-Vida A; Juanpere-Rodero N; Arpi O; Menéndez S; Soria-Jiménez L; Martínez A; Iarchouk N; Rojo F; Albanell J; Brake R; Rovira A; Bellmunt J
Mol Cancer Res; 2019 Sep; 17(9):1931-1944. PubMed ID: 31160383
[TBL] [Abstract][Full Text] [Related]
27. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
28. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
30. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
31. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment.
Bariwal J; Kumar V; Chen H; Bhattarai RS; Peng Y; Li W; Mahato RI
J Control Release; 2019 Sep; 309():231-243. PubMed ID: 31330213
[TBL] [Abstract][Full Text] [Related]
33. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
[TBL] [Abstract][Full Text] [Related]
35. Imidazopyridine linked triazoles as tubulin inhibitors, effectively triggering apoptosis in lung cancer cell line.
Sayeed IB; Vishnuvardhan MVPS; Nagarajan A; Kantevari S; Kamal A
Bioorg Chem; 2018 Oct; 80():714-720. PubMed ID: 30075408
[TBL] [Abstract][Full Text] [Related]
36. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
37. MPT0B169 and MPT0B002, New Tubulin Inhibitors, Induce Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Colorectal Cancer Cells.
Lee CH; Lin YF; Chen YC; Wong SM; Juan SH; Huang HM
Pharmacology; 2018; 102(5-6):262-271. PubMed ID: 30227438
[TBL] [Abstract][Full Text] [Related]
38. FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1α-modulated FattyAcid metabolism.
Guo Y; Yang L; Guo W; Wei L; Zhou Y
Chem Biol Interact; 2021 Dec; 350():109702. PubMed ID: 34648812
[TBL] [Abstract][Full Text] [Related]
39. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
40. Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of α-tubulin acetylation.
Xu H; Wang L; Shi B; Hu L; Gan C; Wang Y; Xiang Z; Wang X; Sheng J
Biomed Pharmacother; 2020 Sep; 129():110441. PubMed ID: 32580047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
